Emcure Pharmaceuticals Stock Price To Earnings To Growth
| EMCURE Stock | 1,373 16.15 1.16% |
Emcure Pharmaceuticals fundamentals help investors to digest information that contributes to Emcure Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Emcure Stock. The fundamental analysis module provides a way to measure Emcure Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emcure Pharmaceuticals stock.
Emcure |
Emcure Pharmaceuticals Company Price To Earnings To Growth Analysis
Emcure Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Emcure Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The price to earnings to growth for all India stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Emcure Fundamentals
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 295.8 B | ||||
| Shares Owned By Insiders | 86.77 % | ||||
| Shares Owned By Institutions | 3.53 % | ||||
| Price To Book | 9.39 X | ||||
| Price To Sales | 3.92 X | ||||
| Revenue | 69.17 B | ||||
| EBITDA | 12.05 B | ||||
| Book Value Per Share | 162.97 X | ||||
| Earnings Per Share | 26.38 X | ||||
| Target Price | 1575.0 | ||||
| Market Capitalization | 270.98 B |
About Emcure Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emcure Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emcure Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emcure Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Emcure Stock
Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.